CN103041365B - Medicament for treating gastric ulcer - Google Patents
Medicament for treating gastric ulcer Download PDFInfo
- Publication number
- CN103041365B CN103041365B CN201310021502.8A CN201310021502A CN103041365B CN 103041365 B CN103041365 B CN 103041365B CN 201310021502 A CN201310021502 A CN 201310021502A CN 103041365 B CN103041365 B CN 103041365B
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- gram
- parched
- brown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 75
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 41
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 41
- 210000003038 endothelium Anatomy 0.000 claims abstract description 16
- 239000009306 yunnan baiyao Substances 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 14
- 241000208340 Araliaceae Species 0.000 claims description 14
- 241000180649 Panax notoginseng Species 0.000 claims description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 14
- 235000008597 Diospyros kaki Nutrition 0.000 claims description 13
- 239000010271 massa medicata fermentata Substances 0.000 claims description 13
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 abstract description 33
- 210000002784 stomach Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 11
- 231100000957 no side effect Toxicity 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 241001313857 Bletilla striata Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000011511 Diospyros Nutrition 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000008081 Rheum officinale Nutrition 0.000 abstract 1
- 240000001745 Rheum palmatum Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 38
- 231100000397 ulcer Toxicity 0.000 description 38
- 230000000694 effects Effects 0.000 description 31
- 208000024891 symptom Diseases 0.000 description 23
- 210000000952 spleen Anatomy 0.000 description 15
- 208000008469 Peptic Ulcer Diseases 0.000 description 14
- 201000006549 dyspepsia Diseases 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 11
- 230000008673 vomiting Effects 0.000 description 11
- 206010047700 Vomiting Diseases 0.000 description 10
- 208000011906 peptic ulcer disease Diseases 0.000 description 10
- 206010067171 Regurgitation Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 229940037467 helicobacter pylori Drugs 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 241000590002 Helicobacter pylori Species 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 210000004211 gastric acid Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 206010000087 Abdominal pain upper Diseases 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000000718 duodenal ulcer Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000027119 gastric acid secretion Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000000660 Pyloric Stenosis Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 206010000059 abdominal discomfort Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 210000001187 pylorus Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000001562 sternum Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010042220 Stress ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000001175 peptic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- -1 stress Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000008710 Amebic Dysentery Diseases 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950002342 bisfentidine Drugs 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 description 1
- 229950008491 ilaprazole Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310021502.8A CN103041365B (en) | 2013-01-06 | 2013-01-06 | Medicament for treating gastric ulcer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310021502.8A CN103041365B (en) | 2013-01-06 | 2013-01-06 | Medicament for treating gastric ulcer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103041365A CN103041365A (en) | 2013-04-17 |
CN103041365B true CN103041365B (en) | 2014-08-27 |
Family
ID=48054376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310021502.8A Expired - Fee Related CN103041365B (en) | 2013-01-06 | 2013-01-06 | Medicament for treating gastric ulcer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103041365B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104288510A (en) * | 2014-10-11 | 2015-01-21 | 中山百鸥医药科技有限公司 | Traditional Chinese medicine composition for treating gastric ulcer |
CN104721679A (en) * | 2014-12-29 | 2015-06-24 | 倪建平 | Medicine for treating gastrointestinal diseases |
CN105999156A (en) * | 2016-06-22 | 2016-10-12 | 黄欢 | Traditional Chinese veterinary medicine capable of promoting poultry growth |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766774A (en) * | 2010-04-07 | 2010-07-07 | 泰一和浦(北京)中医药研究院有限公司 | Chinese medicine composite for treating duodenal ulcer and preparation method thereof |
CN101773633A (en) * | 2010-04-08 | 2010-07-14 | 泰一和浦(北京)中医药研究院有限公司 | Chinese medicine composition for treating gastric ulcer and preparation method thereof |
CN102824587A (en) * | 2011-07-07 | 2012-12-19 | 随洪涛 | Traditional Chinese medicinal formula for treating gastropathy |
-
2013
- 2013-01-06 CN CN201310021502.8A patent/CN103041365B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766774A (en) * | 2010-04-07 | 2010-07-07 | 泰一和浦(北京)中医药研究院有限公司 | Chinese medicine composite for treating duodenal ulcer and preparation method thereof |
CN101773633A (en) * | 2010-04-08 | 2010-07-14 | 泰一和浦(北京)中医药研究院有限公司 | Chinese medicine composition for treating gastric ulcer and preparation method thereof |
CN102824587A (en) * | 2011-07-07 | 2012-12-19 | 随洪涛 | Traditional Chinese medicinal formula for treating gastropathy |
Also Published As
Publication number | Publication date |
---|---|
CN103041365A (en) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104001111B (en) | Traditional Chinese medicine composition for treating stomach diseases | |
CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
CN104940784B (en) | A kind of Chinese medicine composition for treating chronic gastritis | |
CN104258330A (en) | Traditional Chinese medicinal composition for treating chronic gastritis | |
CN103041365B (en) | Medicament for treating gastric ulcer | |
CN102430105B (en) | Traditional Chinese medicine composite for treating chronic gastritis | |
CN102302662A (en) | Traditional Chinese medicine composition for treating atrophic gastritis | |
CN104352924A (en) | Traditional Chinese medicine formula for treating stomach cancer and preparation method of traditional Chinese medicine formula | |
CN101036717A (en) | Orally taken type Chinese traditional medicine combination for curing irritable bowel syndrome | |
CN103316175B (en) | Traditional Chinese medicine powder, and preparation method and application thereof | |
CN104147524A (en) | Traditional Chinese medicine preparation for treating peptic ulcer | |
CN100396311C (en) | Medicine for treating recurrent peptic ulcer | |
CN103550684B (en) | A kind of Chinese medicine composition for the treatment of stomach carbuncle | |
CN102895392B (en) | Chinese medicine for treating duodenal ulcer | |
CN105343806A (en) | Traditional Chinese medicine preparation for treating gastritis and gastric ulcer | |
CN100534507C (en) | Oral Chinese traditional medicine composition for treating chronic enteritis | |
CN101040992A (en) | Medicine for curing dysphagia | |
CN105106645A (en) | Traditional Chinese medicine for treating gastric ulcer for Chinese medicine internal medicine | |
CN105148231A (en) | Traditional Chinese medicine used for treating gastric ulcers | |
CN104288510A (en) | Traditional Chinese medicine composition for treating gastric ulcer | |
CN104758620A (en) | Liver-soothing and bladder-relieving agent for patients with cholecystitis and preparation method of liver-soothing and bladder-relieving agent | |
CN104399038A (en) | Drug for treating gastritis and preparation method thereof | |
CN104707069A (en) | Traditional Chinese medicine for treating gastric ulcer | |
CN105727127A (en) | Traditional Chinese medicinal prescription for treating gastric cancer and preparation method of traditional Chinese medicinal prescription | |
CN103961632A (en) | Traditional Chinese medicinal composition for treating gastric ulcer and duodenal ulcer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LIU YANFANG Free format text: FORMER OWNER: ZHOU ZHIJIAN Effective date: 20140716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Yanfang Inventor after: Liu Jianjun Inventor after: Liu Jianzhong Inventor before: Zhou Zhijian Inventor before: Zhang Huijuan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHOU ZHIJIAN ZHANG HUIJUAN TO: LIU YANFANG LIU JIANJUN LIU JIANZHONG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140716 Address after: 262500 Shandong province Qingzhou City Linglong Mountain Road No. 4138 Weifang Yidu Central Hospital Applicant after: Liu Yanfang Address before: 262500 Shandong province Qingzhou City Linglong Mountain Road No. 4138 Applicant before: Zhou Zhijian |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BU JIANWEI Effective date: 20141028 Owner name: LIU SHUYIN Free format text: FORMER OWNER: LIU YANFANG Effective date: 20141028 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 262500 WEIFANG, SHANDONG PROVINCE TO: 035400 XINZHOU, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141028 Address after: 035400 Shanxi province Dingxiang County River town as Village No. 26 Patentee after: Liu Shuyin Patentee after: Bo Jianwei Address before: 262500 Shandong province Qingzhou City Linglong Mountain Road No. 4138 Weifang Yidu Central Hospital Patentee before: Liu Yanfang |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20160106 |
|
CF01 | Termination of patent right due to non-payment of annual fee |